MTM Services Underused in Part D Drug Plans

Eileen Oldfield, Associate Editor
Published Online: Friday, August 15, 2014
Follow Pharmacy_Times:
Less than half of Medicare enrollees eligible for MTM services receive consultations from a clinical pharmacist.

Although the US Centers for Medicare and Medicaid Services (CMS) requires all Medicare prescription drug (Part D) plans to provide medication therapy management (MTM) services to beneficiaries meeting certain criteria, less than half of eligible enrollees receive those services.
 
According to an analysis from Avalere Health, CMS estimates 25% of Part D enrollees are eligible for MTM services. Among the top 10 Medicare Part D carriers, however, MTM enrollment rates ranged from 4.6% to 17.5%, for an average of 11% of enrollees receiving the services.
 
In 2012, Medicare beneficiaries were eligible for MTM services if they had at least 2 chronic conditions, were taking at least 3 medications, and had annual drug spending exceeding $3100. Although Part D plans are also required to offer comprehensive medication review (CMR) to all MTM enrollees, Avalere’s analysis showed considerable variation in implementation of those services. CMR enrollment ranged from 2.4 to 74%, with an average of 9.6% of enrollees receiving the services.
 
“With only half of enrollees eligible for MTM programs receiving benefits, the Avalere analysis shows that these valuable services are under-used in Medicare,” Avalere Health CEO Dan Mendelson said in a press release. “As regulators consider reforms, they will need to balance access to services with the operation realities faced by health plans.”
 
Despite the low participation in MTM programs, Medicare Advantage prescription drug plan enrollees were 3 times as likely as those in standalone prescription drug plans to receive CMR. Patients in these plans were 4 times as likely to receive an intervention as a result of CMR, including either outreach to a prescriber or a change in therapy, Avalere reported.


Related Articles
The National Community Pharmacists Association issued the following statement today from CEO B. Douglas Hoey, RPh, MBA in response to a study by the Centers for Medicare & Medicaid Services of beneficiary access to discounted copays at “preferred” pharmacies in Medicare drug plans.
Today Reps. Doug Collins (R-Ga.) and Dave Loebsack (D-Iowa) introduced H.R. 5815, The Generic Drug Pricing Fairness Act, which creates greater transparency in how pharmacy benefit managers reimburse pharmacies for generic prescription drugs under Medicare Part D, and the Federal Employees Health Benefits Program. The National Community Pharmacists Association endorsed the bill, which goes further than legislation the same two Congressmen introduced earlier year that has the same remedies, but only applied to Medicare Part D.
Medicare changes course on proposed payment cuts to radiation therapy in 2015 Medicare Physician Fee Schedule
Latest Issues
$auto_registration$